Pomerantz LLP is investigating Qiagen N.V. for potential securities fraud following the company's announcement of a 1% decline in net sales and a 5% drop in QuantiFERON product sales in Q1 2026. This news caused Qiagen's stock to fall over 10% in one day. The investigation targets whether Qiagen's officers or directors engaged in unlawful business practices. Investors affected by this may consider joining the class action lawsuit.
Crédit Agricole Brie Picardie conducted share buybacks from May 11 to May 15, 2026, under Article 5 of the MAR regulation. The bank repurchased a total of several thousand shares daily at prices ranging from approximately €33.27 to €34.98 on the XPAR...
The global single malt whiskey market, valued at $2.4 billion in 2025, is projected to grow to $3 billion by 2032 with a CAGR of 3.2%. Growth is fueled by rising consumer interest in premium artisanal spirits, expanding global distribution, and innov...
US defense contractors are requesting a postponement of the January 1, 2027 ban on sourcing rare earth magnets from China for military contracts. These magnets, crucial for advanced weapons and tech products, are currently dominated by Chinese produc...
The Delhi High Court has directed Apple to fully cooperate with India's Competition Commission in its ongoing antitrust investigation into Apple's App Store payment system, which charges developers up to 30%. Apple had resisted providing financial di...
AL Sydbank A/S continued its share buyback programme in week 20, purchasing 36,000 shares at an average price of around DKK 528 per share, totaling approximately DKK 19 million. The buyback, announced in February 2026 and running until January 2027, ...
